

HUA MEDICINE
華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2552)

Number of shares to which this form of proxy relates(Note 1)	

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 26, 2025

I/We(Note 2) _____

of _____

being the registered holder(s) of shares of US$0.001 each in the issued share capital of Hua Medicine (the "Company") hereby appoint the Chairman of the meeting(Note 3) or _____

of _____

as my/our proxy to attend, act and vote for me/us and on my/our behalf as directed below at the annual general meeting (the "AGM") of the Company to be held at the Company's headquarter in Shanghai at Building 2, Lane 36, Xuelin Road, Pudong New Area, Shanghai, PRC on Thursday, June 26, 2025 at 10:30 a.m. (and at any adjournment thereof).

Please tick ("√") the appropriate boxes to indicate how you wish your vote(s) to be cast(Note 4).

	ORDINARY RESOLUTIONS	FOR	AGAINST
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2024.		
2(a).	To re-elect Mr. George Chien Cheng LIN as executive director of the Company.		
2(b).	To re-elect Mr. Yiu Wa Alec TSUI as independent non-executive director of the Company.		
2(c).	To re-elect Mr. Yiu Leung Andy CHEUNG as independent non-executive director of the Company.		
2(d).	To authorize the board of directors of the Company to fix the respective directors' remuneration.		
3.	To re-appoint Deloitte Touche Tohmatsu as Company's auditor and to authorize the board of directors of the Company to fix their remuneration.		
4.	To give a general mandate to the directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution.		
5.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution and/or to resell treasury B71h.1(and/orlS23.4286-1.6786TD.1()-31rmnt)-dTD.1()-und B71h.1(as)-351.Lisra remuneration.		
	5.		